A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

NCT00400478 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

683

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)
Follicular NHL Grade 3b

Interventions

DRUG: Rituximab

Sponsor

Arbeitsgemeinschaft medikamentoese Tumortherapie

Collaborators

[object Object]